



## **Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018**

November 5, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2018-- [Seres Therapeutics, Inc.](#) (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9877087. To join the live webcast, please visit the "Investors and Media" section of the Seres website at [www.serestherapeutics.com](http://www.serestherapeutics.com).

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

### **About Seres Therapeutics**

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent *C. difficile* infection. SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate ulcerative colitis. Seres is developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary *C. difficile* infection. Seres is also developing SER-401 to augment the efficacy of immuno-oncology treatment. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com). Follow us on Twitter [@SeresTx](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181105005273/en/>

Source: Seres Therapeutics, Inc.

### **IR or PR:**

Seres Therapeutics

Carlo Tanzi, Ph.D., 617-203-3467

Vice President Investor Relations and Corporate Communications

[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)